Can Total Assets from 2010 to 2026
| CANF Stock | USD 4.59 0.37 8.77% |
Total Assets | First Reported 2011-09-30 | Previous Quarter 7.7 M | Current Value 7.7 M | Quarterly Volatility 4.1 M |
Check Can Fite financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Can Fite's main balance sheet or income statement drivers, such as Depreciation And Amortization of 6 K, Interest Expense of 12 K or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 18.39, Dividend Yield of 0.0 or PTB Ratio of 2.95. Can financial statements analysis is a perfect complement when working with Can Fite Valuation or Volatility modules.
Can | Total Assets | Build AI portfolio with Can Stock |
The Total Assets trend for Can Fite Biopharma offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Can Fite is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Can Fite's Total Assets Growth Pattern
Below is the plot of the Total Assets of Can Fite Biopharma over the last few years. Total assets refers to the total amount of Can Fite assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Can Fite Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Can Fite's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Can Fite's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 9.12 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Can Total Assets Regression Statistics
| Arithmetic Mean | 9,359,682 | |
| Geometric Mean | 8,314,206 | |
| Coefficient Of Variation | 46.53 | |
| Mean Deviation | 2,800,053 | |
| Median | 9,283,000 | |
| Standard Deviation | 4,354,971 | |
| Sample Variance | 19T | |
| Range | 18.6M | |
| R-Value | 0.42 | |
| Mean Square Error | 16.6T | |
| R-Squared | 0.18 | |
| Significance | 0.09 | |
| Slope | 364,482 | |
| Total Sum of Squares | 303.5T |
Can Total Assets History
Other Fundumenentals of Can Fite Biopharma
Can Fite Total Assets component correlations
Click cells to compare fundamentals
About Can Fite Financial Statements
Can Fite stakeholders use historical fundamental indicators, such as Can Fite's Total Assets, to determine how well the company is positioned to perform in the future. Although Can Fite investors may analyze each financial statement separately, they are all interrelated. For example, changes in Can Fite's assets and liabilities are reflected in the revenues and expenses on Can Fite's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Can Fite Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Assets | 10.5 M | 10.5 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Can Fite Correlation against competitors. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Can Biotechnology industry sustain growth momentum? Does Can have expansion opportunities? Factors like these will boost the valuation of Can Fite. Projected growth potential of Can fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Can Fite demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding Can Fite Biopharma requires distinguishing between market price and book value, where the latter reflects Can's accounting equity. The concept of intrinsic value - what Can Fite's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Can Fite's price substantially above or below its fundamental value.
It's important to distinguish between Can Fite's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Can Fite should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Can Fite's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.